PARS2 and plasma cell myeloma: A targeted proteomic approach using a mass cytometry panel of myeloma response markers after a 24-h exposure to ProRS inhibitors (Supplementary Fig. S4A and B) supports and extends the observed changes in the protein abundance of MYC, MCL-1 and SDC1.